Stay updated with breaking news from Gnrh Agonists. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting.
Alicia Morgans, MD, MPH, discusses androgen deprivation therapy and its role in treating prostate cancer.
Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.
In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.
Although the disease afflicts at least 1 out of every 10 women, endometriosis remains a conundrum for patients and their physicians.